SD Biotechnologies

At a glance

SD Biotechnologies filed 35 disclosures in the last 12 months, including 2 5% holder and 1 m&a. The most recent key filing was on Mar 24.

Revenue for 2025 was ₩30.1B, down 12.8% on 2024. It made an operating loss of ₩6.3B. Debt was 61% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩12.4B and operating loss of ₩2.4B.

The 2025 annual report lists 63 employees with an average tenure of 2.5 years and average pay of ₩56.8M, #1135 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩69.7M each on average. It paid no cash dividend for 2025. 대원제약(주) and related parties held 72.90% at year end.

From the 2025 annual report

Staff: 63 (30 men, 33 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩3.6B. Directors and auditors: 4, paid ₩418.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

대원제약(주) holds 72.90%; with 0 related parties the group holds 72.90% of common shares at year end.

Source: 2025 annual business report (DART). How figures are combined

Financial summary